UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2009

OR

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-50068

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

(Exact name of registrant as specified in its charter)

UTAH

(State or other jurisdiction of incorporation or organization)

4233 E. Magnolia Avenue

Phoenix, AZ

85034

(Address of principal executive offices, including zip code.)

(602) 561-9177

(telephone number, including area code)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.

YES [X] NO [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer, “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ]

Non-accelerated filer [ ] Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES [X] NO [ ]

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 15,520,533 as of July 30, 2009.

PART I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

	Balance Sheets	F-1
	Statements of Operations and Comprehensive Loss	F-2
	Statements of Stockholders’ Equity	F-3
	Statements of Cash Flows	F-4
	Notes to Financial Statements	F-5

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

BALANCE SHEETS


	June 30,			December 31,
	2009			2008
As at	(Unaudited)			(Audited)

		$			$
ASSETS
CURRENT

Cash and cash equivalents		4,354			5,146

TOTAL ASSETS		4,354			5,146

LIABILITIES
CURRENT

Accounts payable and accrued liabilities		18,560			20,661
Due to a related party (Note 5)		18,000			10,000

TOTAL LIABILITIES		36,560			30,661

STOCKHOLDERS’ EQUITY (DEFICIENCY)

COMMON STOCK
Authorized: 200,000,000 shares, $0.001 par value
Issued and outstanding: 15,520,533 shares
(December 31, 2008: 15,520,533 shares)		15,521			15,521

ADDITIONAL PAID-IN CAPITAL		4,833,164			4,833,164

DEFICIT		(4,880,891	)		(4,874,200	)

TOTAL STOCKHOLDERS’ EQUITY (DEFICIENCY)		(32,206	)		(25,515	)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)		4,354			5,146

NOTE 1 – NATURE AND CONTINUANCE OF OPERATIONS

See accompanying Notes to the Financial Statements

F-1

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)


	Three Month Period Ended June 30,						Six Month Period Ended June 30,
	2009			2008			2009			2008
	$			$			$			$

OTHER INCOME		-			1			1			2



GENERAL AND ADMINISTRATIVE EXPENSES		(3,714	)		(4,706	)		(6,692	)		(7,160	)


NET (LOSS) AND COMPREHENSIVE (LOSS) FOR THE PERIOD		(3,714	)		(4,705	)		(6,691	)		(7,158	)

LOSS PER SHARE

Basic and diluted		(0.00	)		(0.00	)		(0.00	)		(0.00	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING

Basic and diluted		15,520,533			15,520,533			15,520,533			15,520,533

See accompanying Notes to the Financial Statements

F-2

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIENCY)

(Unaudited)

	Common Shares		Stock Amount		Additional Paid in Capital		Deficit Accumulated Since Inception			Total Stockholders’ Equity (Deficiency)
				$		$		$			$

Balance, December 31, 2004		11,520,533		11,521		4,797,164		(4,786,464	)		22,221

Issue of common stock at a price of $0.01 per share pursuant to the exercise of warrants		4,000,000		4,000		36,000		-			40,000

Net loss and comprehensive loss for the year ended December 31, 2005		-		-		-		(22,325	)		(22,325	)

Balance, December 31, 2005		15,520,533		15,521		4,833,164		(4,808,789	)		39,896

Net loss and comprehensive loss for the year ended December 31, 2006		-		-		-		(22,122	)		(22,122	)

Balance, December 31, 2006		15,520,533		15,521		4,833,164		(4,830,911	)		17,774

Net loss and comprehensive loss for the year ended December 31, 2007		-		-		-		(20,940	)		(20,940	)

Balance, December 31, 2007		15,520,533		15,521		4,833,164		(4,851,851	)		(3,166	)

Net loss and comprehensive loss for the year ended December 31, 2008		-		-		-		(22,349	)		(22,349	)

Balance, December 31, 2008		15,520,533		15,521		4,833,164		(4,874,200	)		(25,515	)

Net loss and comprehensive loss for the period ended June 30, 2009		-		-		-		(6,691	)		(6,691	)

Balance, June 30, 2009		15,520,533		15,521		4,833,164		(4,880,891	)		(32,206	)

See accompanying Notes to the Financial Statements

F-3

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Month Period Ended June 30, 2009			Six Month Period Ended June 30, 2008
		$			$
OPERATING ACTIVITIES
Net Loss		(6,691	)		(7,158	)

Change in operating assets and liabilities:
- (Decrease) increase in accounts payable and accrued liabilities		(2,101	)		(7,139	)

Net cash (used in) operating activities		(8,792	)		(14,297	)

FINANCING ACTIVITIES
Advance from related party		8,000			-

Net cash provided by financing activities		8,000			-

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(792	)		(14,297	)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		5,146			20,109

CASH AND CASH EQUIVALENTS AT END OF PERIOD		4,354			5,812

SUPPLEMENTAL CASH FLOWS INFORMATION
Interest expense	-	-
Taxes	-	-

NON-CASH FINANCING ACTIVITIES
None	-	-

See accompanying Notes to the Financial Statements

F-4

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

June 30, 2009

NOTE 1 – NATURE AND CONTINUANCE OF OPERATIONS

These unaudited interim financial statements have been prepared in accordance with the instructions to SEC Form 10-Q. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted pursuant to such instructions. These unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto as at December 31, 2008.

In the opinion of the Company’s management, all adjustments considered necessary for a fair presentation of these unaudited financial statements have been included and all such adjustments are of a normal, recurring nature. Operating results for the six-month period ended June 30, 2009 are not necessarily indicative of the results that can be expected for the year ended December 31, 2009.

The Company does not currently have an active business which it is developing. It has no revenue other than nominal interest income and has accumulated losses of $4,880,891. Until a business is acquired or developed and a self-sustaining level of operations is attained, any future financing will likely involve the further issuance of capital stock. The Company’s financial statements were prepared using generally accepted accounting principles applicable to a going concern, which contemplate the realization of assets and discharge of liabilities in the normal course of business. Management intends to secure additional financing through the issuance of stock. However, there can be no assurance that management will be successful in its efforts to secure additional financing through the issuance of common shares, or that it will ever develop a business, which is self-supporting. Such limitations could have a material adverse effect on the Company’s financial condition or operations, and these financial statements do not include any adjustments that could result therefrom. These factors together raise substantial doubt about its ability to continue as a going concern.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Cash and cash equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. As at June 30, 2009 and December 31, 2008, the Company has $nil and $nil cash equivalents and $nil and $nil are over the federally insured limit.

Advertising costs

All advertising costs are expensed as incurred. During the periods ended June 30, 2009 and 2008 the Company did not incur any advertising costs.

Stock-based compensation

The Company has adopted SFAS No. 123R "Share Based Payments" in accounting for stock options and similar equity instruments. Accordingly, compensation costs attributable to stock options or similar equity instruments granted to employees are measured at the fair value at the grant date, and expensed over the expected vesting period with a corresponding increase to additional paid-in capital. Transactions in which goods or services are received from non-employees in exchange for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. As at June 30, 2009 and December 31, 2008 and for the periods then ended the Company has not issued any stock options or similar equity instruments.

F-5

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

June 30, 2009

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Comprehensive income (loss)

In accordance with SFAS 130, “Reporting Comprehensive Income” (“SFAS 130"), comprehensive income consists of net income and other gains and losses affecting stockholders’ equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses when the functional currency is not U.S. dollars, and minimum pension liability.

For the periods ended June 30, 2009 and 2008, the Company’s financial statements include none of the additional elements that affect comprehensive income (loss). Accordingly, net loss and comprehensive loss are identical.

Loss per share

Basic loss per common share has been calculated based on Halo’s weighted average number of common shares outstanding during the period. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive.

On April 1, 2009, the Company adopted Financial Accounting Standards Board (“FASB”) FSP EITF 03-6-1, Determining Whether Instruments Granted in Share-Based Payment Transactions are Participating Securities. FSP EITF 03-6-1 addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and affects entities that accrue cash dividends on share-based payment awards during the awards’ service period when the dividends do not need to be returned if the employees forfeit the awards. FSP EITF 03-6-1 states that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders and, therefore, need to be included in the earnings allocation in computing earnings per share under the two-class method. The adoption of FSP EITF 03-6-1 does not have a material impact on the Company’s financial statements.

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Financial instruments and financial risk

The Company’s financial instruments consist of cash and cash equivalents and accounts payable and accrued liabilities and due from a related party. It is management’s opinion that the Company is not exposed to significant interest rate, foreign currency fluctuation risks or credit risks arising from these financial instruments and, unless otherwise noted, that the fair value of the current assets and liabilities approximates their carrying values due to their short-term nature.

Translation of foreign currencies

The Company’s functional currency is U.S. dollars and unless otherwise indicated all amounts in these financial statements are stated in U.S. dollars.

F-6

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

June 30, 2009

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Translation of foreign currencies (continued)

Revenues and expenses arising from foreign currency transactions are translated into United States dollars at the rates of exchange prevailing when the transactions occur. Monetary assets and liabilities denominated in foreign currencies are translated into United States dollars at the rates prevailing on the balance sheet date. Other assets and liabilities are translated into United States dollars at the rates prevailing on the transaction dates. Exchange gains and losses are recorded as income or expense in the period in which they occur.

Income taxes

The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. In estimating future tax consequences, all expected future events other than enactment of changes in the tax laws or rates are considered.

Due to the uncertainty regarding the Company’s profitability, the deferred tax benefits of its losses have been fully reserved for and no net tax benefit has been recorded in the financial statements.

Recent accounting pronouncements

In June 2009, the FASB issued FASB No. 168, the FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles - a replacement of FASB Statement No. 162 (“SFAS 168”). SFAS 168 establishes the FASB Accounting Standards Codification as the source of authoritative accounting principles recognized by the FASB to be applied by non-governmental entities in the preparation of financial statements in conformity with GAAP in the United States. SFAS 168 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. The adoption of the standard will not have a material impact on the Company.

In June 2009, the FASB issued FASB No. 166, Accounting for Transfers of Financial Assets — an amendment of FASB Statement No. 140 (“SFAS 166”). SFAS 166 requires additional disclosures about the transfer and derecognition of financial assets and eliminates the concept of qualifying special-purpose entities under SFAS 140. SFAS 166 is effective for fiscal years beginning after November 15, 2009. The adoption of the standard will not have a material impact on the Company.

In May 2009, the FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 165, “Subsequent Events.” SFAS No. 165 is intended to establish general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. SFAS No. 165 requires disclosure of the date through which an entity has evaluated subsequent events and the basis for that date, and is effective for interim and annual periods ending after June 15, 2009. The Company does not expect the adoption of SFAS No.165 to have a material effect on the Company’s financial statements.

F-7

HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

June 30, 2009

NOTE 3– COMMON STOCK

As at June 30, 2009 and December 31, 2008, there are no shares subject to warrants, agreements or options.

NOTE 4 – INCOME TAXES

No provision for income taxes has been made for the years presented as the Company incurred net losses.

The potential benefit of net operating loss carry forwards has not been recognized in the financial statements since the Company cannot be assured that it is more likely than not that such benefit will be utilized in future years.

The approximate tax effects of each type of temporary difference that gives rise to future tax assets are as follows:

	Period Ended June 30, 2009			Year Ended December 31, 2008
	$			$
Net operating loss carry forwards (expiring in 2008 to 2028)		3,762,099			3,755,408

Statutory tax rate		35%			35%

Deferred tax assets - net operating loss carry forwards		1,316,735			1,314,393

Less: Valuation allowance		(1,316,735	)		(1,314,393	)

Net deferred tax assets		-			-

NOTE 5 – RELATED PARTY TRANSACTIONS

As at June 30, 2009, the amount of $18,000 (December 31, 2008 - $10,000) is due to the President of the Company for cash advanced to the Company. This advance is non-interest bearing, unsecured and due on demand.

F-8

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

This quarterly report contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars. All references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report the terms “we”, “us”, “our”, the “Company” and “HALO” means

Health Anti-Aging Lifestyle Options, Inc., unless otherwise indicated.

General

The Company was incorporated under the laws of Utah as Daur & Shaver, Inc. on October 24, 1986. On August 31, 1987, the Company completed the acquisition of all of the outstanding common shares of Western Antenna Research, Inc. a Colorado corporation. The Company’s name was subsequently changed to Western Antenna Corporation. After two years of unsuccessful operations Western Antenna Research, Inc. was abandoned, the name of the Company was changed to Hortitech, Inc. and the Company was reclassified as a development stage enterprise on November 29, 1989. Subsequently, the name of the Company was changed to MicroAccel, Inc. on February 2, 2000.

Effective February 28, 2002, the Company issued 11,614,133 common shares to acquire 99.65% of the outstanding common stock of Network Lifestyle Radio Corp. (“NLR”). The share exchange was on a one share for one share basis. The Company subsequently changed its name from MicroAccel to Health Anti-Aging Lifestyle Options, Inc.

On March 31, 2003, the Company completed Compromise and Settlement Agreements to rescind certain Share Exchange Agreements entered into with former shareholders of NLR. The transactions resulted in the Company transferring and delivering directly and indirectly 5,452,500 common shares in NLR to former directors and executive officers of the Company, who were also prior shareholders of NLR; 4,981,500 common shares in NLR to prior shareholders of NLR and 1,180,133 common shares in NLR to NLR’s treasury on behalf of the 22 former NLR shareholders who did not participate in the rescission. The Company received from the former shareholders of NLR an aggregate of 10,205,500 shares of its own common stock, which the Company cancelled.

We are a development stage company and have not yet generated or realized any revenues from our business operations. Operating capital has been raised through the Company's shareholders. We have no revenue other than interest income and have accumulated losses during the development stage of $4,880,891. We expect to generate operating losses during some or all of our planned development stages, which raises substantial doubt about our ability to continue as a going concern. In view of these matters, our ability to continue as a going concern is dependant upon our ability to meet our financial requirements, raise additional capital; which will likely involve the further issuance of capital stock, and the success of our future operations.

Plan of Operation

The Company is in the development stage and continues to explore new business opportunities. We have not identified any new business opportunities and have no agreements related to such opportunities. We do not believe that we currently have sufficient revenues to fund all of our anticipated expenses. We will either have to suspend operations until we do raise the cash, or cease operations entirely.

Our plan of operation over the next twelve months is to raise additional capital to maintain the Company in good standing and to explore new business opportunities. We anticipate that additional funding will be in the form of equity financing from the sale of our common stock or as loans from our director. However, we have no assurance that we will be able to raise sufficient funding from the sale of our common stock to fund all of our anticipated expenses. We do not have any arrangements in place for any future equity financing.

Results of Operations

From Inception on October 24, 1986 to June 30, 2009 and for Six months ended June 30, 2009 Compared to June 30, 2008

For the quarter just ended, much of our efforts were directed at locating new business opportunities and maintaining the Company’s regulatory filings. To date, we have not identified any new business opportunities and have no agreements related to such opportunities.

We remain a company in the development stage. Our balance sheet as of June 30, 2009 reflects total assets of $4,354 comprising of cash. We had total liabilities of $36,560 for a working capital deficiency of $32,206. As of June 30, 2009, our President has advanced a total of $18,000 for general working capital. This advance will need to be repaid once funds become available. There can be no assurance that he will continue to advance funds as required or that other methods of financing will be available or accessible on reasonable terms. If additional capital is required we will raise the funds by issuing debt and/or equity securities although we have no current arrangements or agreements to such financings at this time.

For the three months ended June 30, 2009 and 2008: We had a net loss of $3,714 for the three months ended June 30, 2009 compared to a net loss of $4,705 for the three months ended June 30, 2008. The decrease of $991 was to a decrease in general and administrative expenses.

For the six months ended June 30, 2009 and 2008: We experienced a net loss of $6,691 and $7,158 for the six months ended June 30, 2009 and 2008 respectively. This decrease of $467 was due to a decrease in general and administrative expenses.

During the quarter ended June 30, 2009, we did not issue any common stock.

Liquidity

As of the date of this report, the Company has yet to generate any revenues from its business operations.

We had cash on hand of $4,354 as at June 30, 2009 and a working capital deficiency of $32,206 as compared to cash on hand of $5,146 and working capital deficiency of $25,515 as at December 31, 2008.

We believe we cannot sustain our operations from existing working capital and operations over the next twelve months. As we have yet to commence operations, we have not generated any revenues and there can be no assurance that we can generate significant revenues from operations. During the next twelve months, we expect to incur administrative and professional charges associated with preparing, reviewing, auditing and filing our financial statements and our periodic and other disclosure documents to maintain the Company in good standing or the payment of expenses associated with reviewing or investigating any potential business ventures.

We intend to raise additional capital required to fund our financing needs by issuance of debt and/or equity, although the Company has no current arrangements or agreements related to such financings.

As of June 30, 2009, our President has advanced a total of $18,000 for additional working capital but there can be no assurance that he will continue to advance funds as required or that other methods of financing will be available or accessible on reasonable terms.

Our failure to generate revenue and conduct operations since inception raises substantial doubt about the Company’s ability to continue as a going concern. We will require substantial working capital, and currently have inadequate capital to fund all of our business strategies, which could severely limit our operations or cease operations entirely.

Off Balance Sheet Arrangements

We have no off balance sheet arrangements.

Critical Accounting Policies

There have been no material changes in our existing accounting policies and estimates from the disclosures included in our 2008 Form 10-K, except for the newly adopted accounting policies as disclosed in the interim financial statements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the end of the period covered by this report. Based on that evaluation, the Principal Executive Officer and Principal Financial Officer have concluded that these disclosure controls and procedures are effective however the following material deficiencies exist:

(i)	The Company’s management is relying on external consultants for purposes of preparing its financial reporting package; the officers may not be able to identify errors and irregularities in the financial reporting package before its release as a continuous disclosure document.

(ii)	As the Company is governed by one officer who is also the only director, there is an inherent lack of segregation of duties and lack of independent governing board.

(iii)

The Company does not have standard procedures in place to ensure that the financial statements agree to the underlying source documents and accounting records, that all of its transactions are completely reflected in the financial statements.

(iv)	There are no controls in place to ensure that expenses are recorded when incurred, as opposed to when invoices are presented by suppliers, increasing the risk of incomplete expenses and accrued liabilities.

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We know of no material, active or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

The following documents are included herein:

Exhibit No.	Document Description

31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-15(e) and 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.

32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer and Chief Financial Officer).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 30th day of July, 2009.

	HEALTH ANTI-AGING LIFESTYLE OPTIONS, INC.
	(Registrant)

	BY:	DAVID ALLEY
		David Alley
		President, Principal Executive Officer, Principal Accounting Officer, Principal Financial Officer, Secretary/Treasurer, and member of the Board of Directors.

EXHIBIT INDEX

Exhibit No.	Document Description

31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-15(e) and 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.

32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer and Chief Financial Officer).

HEALTH ANTI AGING LIFESTYLE OPTIONS INC 10-Q